Zentek Ltd. specializes in the research and development of graphene and related nanomaterials, focusing on antimicrobial coatings. While the company boasts strong liquidity with a current ratio of 4.65 and low debt levels (Debt/Equity of 0.08), it faces concerns with negative returns on equity (-8.1%) and assets (-6.6%). The recent 5% drop in stock price may reflect market skepticism about its growth potential despite its innovative technology. Overall, while liquidity is a strength, the negative profitability metrics warrant caution for potential investors.
Loading financial metrics...
Revenue fell 93.8% year-over-year from $1.7M to $108K. The decline has persisted for multiple quarters.
Company posted a loss of $-10.4M over the last year, representing 9652.8% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $5.1M over the last year.
Fortress balance sheet: cash covers total debt 8.6×, providing significant financial flexibility.
Excellent liquidity with current ratio of 4.6x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Medical Instruments & Supplies companies of a similar size
Based on 2027-Q1 (June 30, 2026)